By Anna Wrona, MD, PhD Posted: October 2018 The IASLC Africa Conference on Lung Cancer 2018 in Tangier, Morocco, held last spring, provided participants with unique expert perspectives in lung […] Read more
By Shani Shilo, DMD, PhD, andNir Peled, MD, PhD, FCCP Posted: June 2018 On March 6, 2018, the Israeli parliament, the Knesset, held a Science and Technology Committee meeting devoted […] Read more
Natural disasters, such as Hurricane Maria, may have contributed to more acute shortages than previously experienced. By Jorge Garcia, PharmD, MS, MHA, MBA, and Dina B. Dumercy, PharmD, BCOP, BCPS […] Read more
Using Deep Learning Systems to Radiologically Predict Pathologic Invasiveness in Lung Adenocarcinoma
By Masahiro Yanagawa, MD, PhD, andNoriyuki Tomiyama, MD, PhD Posted: April 2018 Improvement in computer capacity, the expansion of computer networks, and the emergence of big data have resulted in […] Read more
By Pedro N. Aguiar Jr., MD, MSc, andGilberto L. Lopes Jr., MD, MBA Posted: April 2018 After often-painful but effective and still incomplete economic reforms, more rational government spending, and […] Read more
By AnnMarie Estrada, IASLC Foundation Director Posted: February 2018 When you think of the IASLC, you think about professional development, networking, and renowned international lung cancer conferences. When you consider […] Read more
By Cynthia L. Kryder, MSPosted: December 2017 Despite genomic advances in the treatment of advanced lung cancer over the past decade, few breakthroughs have emerged in the adjuvant treatment of […] Read more
By Fabrice Barlesi, MD, PhD, and Eric Vallières, MD, FRCSC An article by Cynthia Kryder and Ramón Rami-Porta in the IASLC Lung Cancer News recently highlighted the innovations of the […] Read more
By Gian Piero Bandelli, MD, Federica Ferraresi, WALCE Advocate, and Silvia Novello, MD, PhD On the occasion of World No Tobacco Day 2017, Women Against Lung Cancer in Europe (WALCE), […] Read more
By Cynthia L. Kryder, MS, CCC-Sp Rearrangements in the anaplastic lymphoma kinase (ALK) gene occur in approximately 2% to 7% of patients with advanced non-small cell lung cancer (NSCLC).1 For […] Read more